Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 52

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 52
---
 began focusing our spending on clinical trials and commercialization of the product that has been developed.

 20Table of Contents

Sales and Marketing     

Sales and marketing expenses were $137,825 for the six months ended June 30, 2025, as compared to $401,612  for the six months ended June 30, 2024, a decrease of $263,787, or 66%. The costs include primarily headcount and pre-selling activities for our TAEUS product line. Sales and marketing expenses decreased largely due to our restructuring in the second quarter of 2024. Currently, our marketing efforts are through our website and attendance of key industry meetings.

General and Administrative     

Our general and administrative expenses for the six months ended June 30, 2025 were $1,722,801, compared to $2,851,890 for the six months ended June 30, 2024, a decrease of $1,129,089, or 40%. Our wage and related expenses for the six months ended June 30, 2025 were $482,576, compared to $1,222,478 for the six months ended June 30, 2024. Wage and related expenses in the six months ended June 30, 2025 included $151,551 of stock compensation expense related to the issuance and vesting of options and RSUs for the three months ended June 30, 2025. Our professional fees, which include legal, audit, and investor relations, for the six months ended June 30, 2025 were $719,815, compared to $1,222,199 for the six months ended June 30, 2024.

Other Income     

Other income was $37,395 for the six months ended June 30, 2025, compared to other income of $6,541 for the six months ended June 30, 2024, an increase of $30,915, or 473%, due to increased interest income. For the six months ended June 30, 2025, there were changes in fair value of warrant liability of $470,674.

Net Loss     

As a result of the foregoing, for the six months ended June 30, 2025, we recorded a net loss of $2,262,242, compared to a net loss of $5,004,853 for the six months ended June 30, 2024.

Near-Term Liquidity and Capital Resources